Metabolism and pharmacokinetics of the anti-hepatitis C virus nucleotide prodrug GS-6620

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 1943-1951

  Murakami, Eisuke ^a   Wang, Ting ^a   Babusis, Darius ^a   Lepist, Eve Irene ^a   Sauer, Dorothea ^a   Park, Yeojin ^a   Vela, Jennifer E ^a   Shih, Robert ^a   Birkus, Gabriel ^a   Stefanidis, Dimitrios ^a   Kim, Choung U ^a,b   Cho, Aesop ^a   Ray, Adrian S ^a  

^a GILEAD SCIENCES   (United States)

^b Asan Institute for Life Sciences   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GS 6620; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; HAPLORHINI; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; LIVER CELL; PRIORITY JOURNAL; STOMACH PH;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; CACO-2 CELLS; CELL LINE; CRICETINAE; DOGS; HEPACIVIRUS; HUMANS; MACACA FASCICULARIS; MALE; MESOCRICETUS; PRODRUGS;

EID: 84896950299     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02350-13     Document Type: Article

References (23)

1. Alter HJ. 2005. HCV natural history: the retrospective and prospective in perspective. J. Hepatol. 43: 550 -552. http://dx.doi.org/10.1016/j.jhep.2005. 07.002.
2. El-Serag HB. 2012. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273.e1. http://dx.doi.org/10.1053/j. gastro.2011.12.061.
3. Cho A, Zhang L, Xu J, Lee R, Butler T, Metobo S, Aktoudianakis V, Lew W, Ye H, Clarke M, Doerffler E, Byun D, Wang T, Babusis D, Carey AC, German P, Sauer D, Zhong W, Rossi S, Fenaux M, McHutchison JG, Perry J, Feng J, Ray AS, Kim CU. 2 April 2013. Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. J. Med. Chem. http://dx.doi.org/10.1021/jm400201a.
4. Feng JY, Cheng G, Perry J, Barauskas O, Xu Y, Fenaux M, Eng S, Tirunagari N, Peng B, Yu M, Tian Y, Lee YJ, Stepan G, Lagpacan LL, Jin D, Hung M, Ku KS, Han B, Kitrinos K, Perron M, Birkus G, Wong KA, Zhong W, Kim CU, Carey A, Cho A, Ray AS. 2014. Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrob. Agents Chemother. 58:1930-1942. http://dx.doi.org/10.1128/AAC.02351-13.
5. Lawitz E, Hill J, Marbury T, Hazan L, Gruener D, Webster L, Majauskas R, Morrison R, DeMicco M, German P, Stefanidis D, Svaroskaia E, Arterburn S, Ray A, Rossi S, McHutchison J, Rodriguez-Torres M. 2012. GS-6620, a liver-targeted nucleotide prodrug, exhibits antiviral activity and favorable safety profile over 5 days in treatment naïve chronic HCV genotype 1 subjects, abstr. 1188. 47th Annual Meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain, 18 to 22 April 2012.
6. Birkus G, Wang R, Liu X, Kutty N, MacArthur H, Cihlar T, Gibbs C, Swaminathan S, Lee W, McDermott M. 2007. Cathepsin A is a major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob. Agents Chemother. 51: 1-7. http://dx.doi.org/10.1128/AAC.01367-06.
7. CDER. 2005. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf.
8. Furman PA, Murakami E, Niu C, Lam AM, Espiritu C, Bansal S, Bao H, Tolstykh T, Micolochick Steuer H, Keilman M, Zennou V, Bourne N, Veselenak RL, Chang W, Ross BS, Du J, Otto MJ, Sofia MJ. 2011. Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661. Antiviral research. 91:120-132. http://dx.doi.org/10.1016/ j.antiviral.2011.05.003.
9. Murakami E, Tolstykh T, Bao H, Niu C, Steuer HM, Bao D, Chang W, Espiritu C, Bansal S, Lam AM, Otto MJ, Sofia MJ, Furman PA. 2010. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J. Biol. Chem. 285:34337-34347. http://dx.doi.org/10.1074/jbc.M110.161802.
10. Chou TF, Baraniak J, Kaczmarek R, Zhou X, Cheng J, Ghosh B, Wagner CR. 2007. Phosphoramidate pronucleotides: a comparison of the phosphoramidase substrate specificity of human and Escherichia coli histidine triad nucleotide binding proteins. Mol. Pharm. 4:208-217. http://dx.doi.org/10.1021/mp060070y. (Pubitemid 46640597)
11. Chou TF, Tikh IB, Horta BA, Ghosh B, De Alencastro RB, Wagner CR. 2007. Engineered monomeric human histidine triad nucleotide-binding protein 1 hydrolyzes fluorogenic acyl-adenylate and lysyl-tRNA synthetase-generated lysyl-adenylate. J. Biol. Chem. 282:15137-15147. http://dx.doi.org/10.1074/jbc. M606972200. (Pubitemid 47093345)
12. Imai T. 2006. Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab. Pharmacokinet. 21:173-185. http://dx.doi.org/10.2133/dmpk.21.173.
13. Imai T, Taketani M, Shii M, Hosokawa M, Chiba K. 2006. Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab. Dispos. 34: 1734-1741. http://dx.doi.org/10.1124/dmd.106.009381. (Pubitemid 44427476)
14. Taketani M, Shii M, Ohura K, Ninomiya S, Imai T. 2007. Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci. 81:924-932. http://dx.doi.org/10.1016/j.lfs.2007.07.026. (Pubitemid 47374212)
15. Hiraiwa M. 1999. Cathepsin A/protective protein: an unusual lysosomal multifunctional protein. Cell. Mol. Life Sci. 56:894-907. http://dx.doi.org/10. 1007/s000180050482. (Pubitemid 30019209)
16. Satake A, Itoh K, Shimmoto M, Saido TC, Sakuraba H, Suzuki Y. 1994. Distribution of lysosomal protective protein in human tissues. Biochem. Biophys. Res. Commun. 205:38-43. http://dx.doi.org/10.1006/bbrc.1994.2626. (Pubitemid 24381587)
17. Lepist EI, Phan TK, Roy A, Tong L, Maclennan K, Murray B, Ray AS. 2012. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob. Agents Chemother. 56: 5409 -5413. http://dx.doi.org/10.1128/AAC.01089-12.
18. McGuigan C, Madela K, Aljarah M, Bourdin C, Arrica M, Barrett E, Jones S, Kolykhalov A, Bleiman B, Bryant KD, Ganguly B, Gorovits E, Henson G, Hunley D, Hutchins J, Muhammad J, Obikhod A, Patti J, Walters CR, Wang J, Vernachio J, Ramamurty CV, Battina SK, Chamberlain S. 2011. Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti- HCV agents. J. Med. Chem. 54: 8632- 8645. http://dx.doi.org/10.1021/ jm2011673.
19. McGuigan C, Sutton PW, Cahard D, Turner K, O'Leary G, Wang Y, Gumbleton M, De Clercq E, Balzarini J. 1998. Synthesis, anti-human immunodeficiency virus activity and esterase lability of some novel carboxylic ester-modified phosphoramidate derivatives of stavudine (d4T). Antivir. Chem. Chemother. 9:473-479. (Pubitemid 28556662)
20. McGuigan C, Tsang HW, Sutton PW, De Clercq E, Balzarini J. 1998. Synthesis and anti-HIV activity of some novel chain-extended phosphoramidate derivatives of d4T (stavudine): esterase hydrolysis as a rapid predictive test for antiviral potency. Antivir. Chem. Chemother. 9:109-115. (Pubitemid 28160956)
21. Lenglet S, Antigny F, Vetterli L, Dufour JF, Rossier MF. 2008. Hint2 is expressed in the mitochondria of H295R cells and is involved in steroidogenesis. Endocrinology 149: 5461-5469. http://dx.doi.org/10.1210/en.2008-0400.
22. Martin J, Magnino F, Schmidt K, Piguet AC, Lee JS, Semela D, St-Pierre MV, Ziemiecki A, Cassio D, Brenner C, Thorgeirsson SS, Dufour JF. 2006. Hint2, a mitochondrial apoptotic sensitizer down-regulated in hepatocellular carcinoma. Gastroenterology 130:2179-2188. http://dx.doi.org/10.1053/j.gastro.2006.03.024. (Pubitemid 43816955)
23. Williams ET, Bacon JA, Bender DM, Lowinger JJ, Guo WK, Ehsani ME, Wang X, Wang H, Qian YW, Ruterbories KJ, Wrighton SA, Perkins EJ. 2011. Characterization of the expression and activity of carboxylesterases 1 and 2 from the beagle dog, cynomolgus monkey, and human. Drug Metab. Dispos. 39: 2305-2313. http://dx.doi.org/10.1124/dmd.111.041335.